1. Home
  2. NDLS vs LIXT Comparison

NDLS vs LIXT Comparison

Compare NDLS & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Noodles & Company

NDLS

Noodles & Company

HOLD

Current Price

$6.01

Market Cap

30.7M

ML Signal

HOLD

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

HOLD

Current Price

$2.57

Market Cap

25.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NDLS
LIXT
Founded
1995
2005
Country
United States
United States
Employees
N/A
4
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.7M
25.3M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
NDLS
LIXT
Price
$6.01
$2.57
Analyst Decision
Hold
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
139.8K
38.8K
Earning Date
04-09-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$493,271,000.00
N/A
Revenue This Year
$2.29
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.47
$0.64
52 Week High
$7.09
$6.09

Technical Indicators

Market Signals
Indicator
NDLS
LIXT
Relative Strength Index (RSI) 79.04 34.18
Support Level $0.63 $2.45
Resistance Level N/A $4.45
Average True Range (ATR) 0.58 0.21
MACD 0.03 -0.03
Stochastic Oscillator 66.87 14.29

Price Performance

Historical Comparison
NDLS
LIXT

About NDLS Noodles & Company

Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Share on Social Networks: